Inflexion Sells European LifeCare Group to PE Buyer - InforCapital

London, August 26, 2025 – Inflexion, a leading European mid-market private equity firm, has announced the sale of its stake in European LifeCare Group (ELCG), the continent’s largest provider of vaccination services, to an undisclosed European private equity buyer. The transaction remains subject to regulatory approvals.

Founded over two decades ago, ELCG operates 84 vaccination clinics across Denmark, the UK, the Netherlands, and Sweden. The group offers a broad portfolio of services including travel vaccines, general health immunizations, and mass vaccination programmes. ELCG has also emerged as a trusted partner for clinical vaccine trials with leading pharmaceutical companies such as Sanofi and Pfizer.

Under Inflexion’s ownership, ELCG was transformed from a niche travel vaccination business into a pan-European preventative healthcare platform. The firm supported a founder-led succession, brought in new leadership, and helped deliver digital innovation through Inflexion’s in-house Digital team. Over the course of the investment, ELCG’s revenue nearly tripled, the number of clinics rose by 65%, and annual vaccinations climbed to over 3 million.

Inflexion also backed four acquisitions that enabled ELCG’s successful expansion into the Benelux and Swedish markets. The company’s workforce grew sixfold during the holding period, reflecting increased demand for private and public immunization services and its role as a delivery partner for national health systems including the Danish health authority and the UK’s NHS.

This deal follows a wave of European PE exits in the healthcare space. In 2025 alone, Bridgepoint exited Diaverum, a Swedish dialysis operator, while Nordic Capital sold its stake in ArisGlobal, a pharma safety software provider. PAI Partners is also nearing the sale of its holding in Ethypharm, a specialty pharma group focused on pain and CNS treatments.

European LifeCare Group is expected to continue its growth under new ownership, with a focus on geographic expansion, vaccine innovation, and scaling its partnerships with life sciences firms. CEO Tanja Sølvkjær and the existing management team will remain in place, aiming to build on the momentum created during the Inflexion era.

Inflexion’s exit underscores the firm’s expertise in buy-and-build strategies and platform professionalization in healthcare services, a sector that continues to attract strong investor interest across Europe.